"Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Pe" by Khurram Nasir

Menu

Skip to main content

All Publications

Khurram Nasir, Baptist Health Medical GroupFollow

Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial

Publication Date

2017

Content Type

Article

PubMed ID:

Additional Authors:

Additional authors and institutional affiliations

Citation

JAMA Cardiol (2017) 2(12):1369-1374

Restricted

Available to BHSF community via local IP address or BHSF login.

Find in your library

COinS